



Laboratory Bulletin

Lead	lers	in l	Lab	ora	tory	Me	dic	ine
Loud	1010			, Oi a	LOI y	IVIC	aic	1110

DATE:	2021 November 15
TO:	Edmonton Zone and North Zone – Physicians, Nurses, Directors, and Managers
FROM:	Clinical Biochemistry, Alberta Precision Laboratories (APL) North Sector and DynaLIFE Medical Labs
	Standardization of Reference Intervals (RI) and Comments in Edmonton and North Zones for ALT, AST, Antistreptolysin O, Fecal Osmolality, Urate

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Messages

• Effective **November 24th, 2021**, provincially standardized reference intervals (RIs) and comments for several chemistry tests will be implemented at APL and DynaLIFE laboratories in Edmonton Zone (EZ) and North Zone (NZ) (see Appendix).

Why this is important

- As outlined in the appendix, all sites in EZ and NZ will adopt the new provincially standardized RIs and comments for ALT, AST, Antistreptolysin O, Fecal Osmolality, and Urate.
 - Note that there are two types of ALT and AST reagent in use across the province. Type 2
 reagents generate systematically higher values than Type 1 reagents. ALT and AST reference
 intervals have been developed to reflect the differences in reagent formulation.
- There are no changes to the testing methods in use, but the RI and comment changes will provide more robust and accurate guidance for result interpretation that is reflective of the Alberta population and will support ongoing provincial laboratory standardization efforts.
- New provincial reference intervals are evidence-based and are derived via statistical analysis of provincial population data.

Action Required

Be aware of updates to reference intervals indicated in the below tables (Appendix)

Inquiries and feedback may be directed to

- Dr. Albert Tsui, Clinical Biochemist, APL, 587-782-2674 or albert.tsui@aplabs.ca
- Dr. Josh Raizman, Clinical Biochemist, APL, 780-718-2402 or josh.raizman@aplabs.ca
- Dr. Miranda Brun, Clinical Biochemist, APL, 780-7224123 or miranda.brun2@aplabs.ca
- Dr. Kaila Crawford, General Pathologist, APL, 780-735-2368 or kaila.crawford@aplabs.ca
- DynaLIFE Clinical Chemists, 780-451-3702 ext. 3572 or clinical.chemists@dynalife.ca

This bulletin has been reviewed and approved by

- Dr. Kareena Schnabl, Section Chief, Clinical Biochemistry, North Sector, APL
- Dr. Mathew Estey, Director of Chemistry, DynaLIFE Medical Labs
- Dr. Michael Mengel, Medical Director, North Sector, APL
- Dr. Raymond Lai, Medical Director, DynaLIFE Medical Labs



Leaders in Laboratory Medicine

Appendix

Alanine Aminotransferase (ALT)

Applicable sites	Current RIs			Provincially Standardized RIs			
Edmonton Zone		ing Provinc		ALT Reagent Type 1*:			
University of Alberta Hospital	Standardized RIs for		Age	Gender	RI (U/L)		
Sturgeon Hospital DynaLIFE Medical Labs		ALT Reagent Type 1 See table to the right)		< 18 y	All	< 35	
Edmonton Zone Grey Nuns Hospital	Age	Gender	RI (U/L)		MILV	< 60	
Misericordia Hospital	All	All	< 50	≥ 18 y	M, U, X		
Royal Alexandra Hospital	All	All	~ 30		F	< 40	
Edmonton Zone Cross Cancer Institute Devon General Hospital East Edmonton Health Centre Fort Saskatchewan Community Hospital Leduc Community Hospital Northeast Community Health	Age All	Gender All	RI (U/L) < 50				
Centre Redwater Health Centre Strathcona Community Hospital Westview Health Centre North Zone				ALT F	Reagent Typ	pe 2*:	
Connect Care Sites: Beaverlodge, Fairview, Fox				< 18 y	All	< 40	
Creek, Grande Cache, High					M, U, X	< 70	
Prairie, Manning, McLennan,				≥ 18 y	F	< 50	
Northern Lights Regional Health Centre, Northwest Health	Age	Gender	RI (U/L)		'	< 30	
Centre, Peace River, Valleyview, Spirit River, St. Theresa General	< 18 y	All	< 35				
Hospital	≥ 18 y	M, U, X	< 60 < 40				
Non-Connect Care (Meditech) sites: Athabasca, Barrhead, Boyle, Bonnyville, Cold Lake, Edson, Elk Point, Hinton, Jasper, Lac La Biche, Mayerthorpe, Swan Hills, Slave Lake, Smoky Lake, St. Paul, Whitecourt, Wabasca, Westlock							

d = days; m = months; y = years; M = Male; F = Female; U = Unknown Sex; X = Gender X *There are two types of ALT reagent formulations across the province. Type 2 reagents generate systematically higher values than Type 1, necessitating higher reference interval upper limits.



Aspartate Aminotransferase (AST)

			AS	T Reagent T	Гуре 1*:	
			Age	Gender	RI (U/L)	
Age	Gender	RI (U/L)	< 1 m	All	<100	
< 8 d	All	< 140	1 m to < 1 y	All	<70	
8 d to < 2 y	All	< 60	1 to < 7 y	All	<50	
2 to < 10 y	All	< 50	7 to < 18 y	All	<35	
≥ 10 y	All	< 40	> 40	M, U, X	<45	
			≥ 18 y	F	<35	
			AST Reagent Type 2*:			
			Age	Gender	RI (U/L)	
			< 1 m	All	<115	
			1 m to < 1 y	All	<80	
Same as above			1 to < 7 y	All	<60	
			7 to < 18 y	All	<45	
			> 10 ./	M, U, X	<55	
			= 10 y	F	<45	
	< 8 d 8 d to < 2 y 2 to < 10 y ≥ 10 y	< 8 d All 8 d to < 2 y All 2 to < 10 y All ≥ 10 y All	< 8 d All < 140 8 d to < 2 y All < 60 2 to < 10 y All < 50 ≥ 10 y All < 40	Age Gender RI (U/L) < 8 d	Age Gender RI (U/L) < 8 d	

d = days; m = months; y = years; M = Male; F = Female; U = Unknown Sex; X = Gender X
*There are two types of AST reagent formulations across the province. Type 2 reagents generate systematically higher values than Type 1, necessitating higher reference interval upper limits.



Antistreptolysin O (ASO)

Applicable sites		Current F	RIs	Provincially Standardized RIs*		
				Age	Gender	RI (IU/mL)
Dynal IEE Madical Labo	Age	Gender	RI (kU/L)	< 6 y	All	<101
DynaLIFE Medical Labs	All	All	<250	6 to < 18 y	All	<251
			_	≥ 18 y	All	<201

^{*}Note change in units from kU/L to IU/mL. Pediatric RIs are specific to methodology in use at DynaLIFE. Adult RI is provincially standardized.

Fecal Osmolality

Applicable sites	Current RIs	Provincially Standardized RIs		
University of Alberta Heapital	None	Age	Gender	RI (mmol/kg)
University of Alberta Hospital	None	All	All	284 – 430

Urate

Applicable sites	Current RIs			Provincially Standardized RIs and Comme		
Edmonton Zone Cross Cancer Institute Grey Nuns Hospital Misericordia Hospital Royal Alexandra Hospital				Age 0 to < 5 y 5 to < 10 y	Gender All All	RI (umol/L) 100 – 300 140 – 330
University of Alberta Hospital DynaLIFE Medical Labs	Age	Gender	RI (umol/L)	10 to < 18 y ≥ 18y	M M	160 – 500 200 – 500*
<u>North Zone</u> Connect Care sites: Northern Lights Regional	0 to < 10 y 10 to	All F	100 – 300 180 – 450	10 to < 70 y ≥ 70 y	F	150 – 400* 150 – 500*
Health Centre Peace River	< 18 y	M, U, X	135 – 510 150 – 400	≥ 10 y *Comment app	U, X	150 – 500* all results from
Non-Connect Care (Meditech) sites:	≥ 18 y	M U, X	180 – 500 150 – 500	patients ≥18 y: For patients w	: ith gout on	serum/plasma
Athabasca, Barrhead, Bonnyville, Cold Lake, Edson, Hinton, Lac La Biche,				urate lowering therapy, treat to target a urate of <350 umol/L. (American College of Rheumatology Guidelines for		
Mayerthorpe, Slave Lake, St. Paul, Whitecourt, Westlock	M M I 5			the Manageme	ent of Gout , June 202	, Arthritis &

d = days; m = months; y = years; M = Male; F = Female; U = Unknown Sex; X = Gender X